title: Expression of cell adhesion molecule CD44 in gastric adenocarcinoma and its prognostic importance.
abstract: OBJECTIVE
  To evaluate the relation of cluster of differentiation 44 (CD44) expression with clinicopathological features of gastric adenocarcinoma, and also its effect on prognosis with an emphasis on the differences between intestinal and diffuse types.
  
  
  METHODS
  From 2000 to 2006, 100 patients with gastric adenocarcinoma, who had undergone total or subtotal gastrectomy without any prior treatment, were studied. Haematoxylin and eosin (HE) staining was used for histological evaluation, including the type (Lauren's classification) and grading of the tumor. The expression of CD44 in the gastric adenocarcinoma mucosa and the adjacent mucosa were determined by immunohistochemistry. The survival analysis was obtained using the Kaplan-Meier test.
  
  
  RESULTS
  Of 100 patients, 74 (74%) patients were male. The tumors were categorized as intestinal type (78%) or diffuse type (22%). Sixty-five percent of patients were CD44-positive. CD44 expression was not detected in normal gastric mucosa. Rather, CD44 was more commonly expressed in the intestinal subtype (P=0.002). A significant relation was seen between the grade of tumor and the expression of CD44 (P=0.014). The survival analysis showed a poor prognosis of patients with CD44-positive tumors (P=0.008); and this was more prominent in the intestinal (P=0.001) rather than diffuse type.
  
  
  CONCLUSIONS
  Cell adhesion molecule CD44 is highly expressed in gastric adenocarcinoma. CD44 expression is correlated with a poor prognosis in patients with the intestinal type of gastric adenocarcinoma. CD44 can, therefore, be utilized as a prognostic marker for this group of patients.
authors.affiliation: Department of Pathology, Mashhad University Cancer Research Center, Omid Oncology Hospital, Mashhad, Iran.
authors.forename: Kamran
authors.initials: K
authors.lastname: Ghaffarzadehgan
authors.forename: Mostafa
authors.initials: M
authors.lastname: Jafarzadeh
authors.forename: Hamid Reza
authors.initials: HR
authors.lastname: Raziee
authors.forename: Hamid Reza
authors.initials: HR
authors.lastname: Sima
authors.forename: Ehsan
authors.initials: E
authors.lastname: Esmaili-Shandiz
authors.forename: Hanieh
authors.initials: H
authors.lastname: Hosseinnezhad
authors.forename: Ali
authors.initials: A
authors.lastname: Taghizadeh-Kermani
authors.forename: Omeed
authors.initials: O
authors.lastname: Moaven
authors.forename: Maryam
authors.initials: M
authors.lastname: Bahrani
mesh_terms: D000230:Adenocarcinoma / Q000276:immunology* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D002454:Cell Differentiation; D005260:Female; D005743:Gastrectomy; D005753:Gastric Mucosa / Q000276:immunology; D006801:Humans; D018960:Hyaluronan Receptors / Q000032:analysis*; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D013274:Stomach Neoplasms / Q000276:immunology* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; C497483:CD44 protein, human; D018960:Hyaluronan Receptors